Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules

doi:10.1186/s12951-020-00610-9

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24884

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24884

Title:	Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules
Authors:	Ho, SY;Chen, PR;Chen, CH;Tsai, NM;Lin, YH;Lin, CS;Chuang, CH;Huang, XF;Chan, YL;Liu, YK;Chung, CH;Weng, SL;Liao, KW
Keywords:	LPPC;Gene therapy;Anti-angiogenesis;RBDV;VEGFR
Date:	2020
Issue Date:	2022-08-09T08:09:34Z (UTC)
Publisher:	BMC
Abstract:	Background The anti-angiogenic fusion protein RBDV-IgG1 Fc (RBDV), which comprises the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A), has shown antitumour effects by reducing angiogenesis in vivo. This study used the cationic lipoplex lipo-PEG-PEI-complex (LPPC) to simultaneously encapsulate both the RBDV targeting protein and the RBDV plasmid (pRBDV) without covalent bonds to assess VEGFR targeting gene therapy in mice with melanoma in vivo. Results LPPC protected the therapeutic transgene from degradation by DNase, and the LPPC/RBDV complexes could specifically target VEGFR-positive B16-F10 cells both in vitro and in vivo. With or without RBDV protein-targeting direction, the pRBDV-expressing RBDV proteins were expressed and reached a maximal concentration on the 7th day in the sera after transfection in vivo and significantly elicited growth suppression against B16-F10 melanoma but not IgG1 control proteins. In particular, LPPC/pRBDV/RBDV treatment with the targeting molecules dramatically inhibited B16-F10 tumour growth in vivo to provide better therapeutic efficacy than the treatments with gene therapy with IgG1 protein targeting or administration of a protein drug with RBDV. Conclusions The simultaneous combination of the LPPC complex with pRBDV gene therapy and RBDV protein targeting might be a potential tool to conveniently administer targeted gene therapy for cancer therapy.
URI:	http://dx.doi.org/10.1186/s12951-020-00610-9 https://www.webofscience.com/wos/woscc/full-record/WOS:000527696900001 https://ir.csmu.edu.tw:8080/handle/310902500/24884
Relation:	JOURNAL OF NANOBIOTECHNOLOGY ,2020 ,v18 ,issue 1
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	163	View/Open

Loading...